TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19371314

Group type: EXPERIMENTAL
Intervention: Predose meal at 18.00 h
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Predose meal at 21.00 h
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Postdose meal at 22.10 h
Number of subjects: 36

Group type: COMPARATOR
Intervention: Fasting subjects
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Predose meal at 18.00 h vs fasting subjects
Number of subjects: 36
Study: 17010236

Group type: EXPERIMENTAL
Intervention: 15 mg Zn/d
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: 30 mg Zn/d
Number of subjects: 387

Group type: COMPARATOR
Intervention: 0 mg (placebo)
Number of subjects: 387
Study: 14564645

Group type: EXPERIMENTAL
Intervention: NUMARIS processing with TE=135 ms
Number of subjects: 28

Group type: COMPARATOR
Intervention: LCModel processing with TE=135 ms
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: NUMARIS processing with TE=10 ms
Number of subjects: 28

Group type: COMPARATOR
Intervention: LCModel processing with TE=10 ms
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Relaxation time corrections applied
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Signal intensity ratios from long echo time spectra
Number of subjects: 28
Study: 10029243

Group type: EXPERIMENTAL
Intervention: p24-VLP (500 microg) in alum monthly plus zidovudine 200 mg tds
Number of subjects: 24

Group type: COMPARATOR
Intervention: p24-VLP
Number of subjects: 24

Group type: COMPARATOR
Intervention: zidovudine
Number of subjects: 24
Study: 8681661

Group type: EXPERIMENTAL
Intervention: High-dose continuous nebulization (7.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard-dose continuous nebulization (2.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-dose intermittent nebulization (2.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose intermittent nebulization (7.5 mg)
Number of subjects: 0
Study: 1653138

Group type: EXPERIMENTAL
Intervention: 100 mg sumatriptan
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 6408949

Group type: EXPERIMENTAL
Intervention: Oral disopyramide phosphate
Number of subjects: 124

Group type: COMPARATOR
Intervention: Oral quinidine sulfate
Number of subjects: 124
Study: 31778522

Group type: EXPERIMENTAL
Intervention: Fear ads (N = 52)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Humor ads (N = 56)
Number of subjects: 108
Study: 28386945

Group type: EXPERIMENTAL
Intervention: Diclofenac potassium for oral solution (active treatment)
Number of subjects: 1272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1272
Study: 26808852

Group type: EXPERIMENTAL
Intervention: Interval running training
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 8
Study: 24251641

Group type: EXPERIMENTAL
Intervention: rGLP-1 at 5.0 pmol/kg/min
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: rGLP-1 at 1.25 pmol/kg/min
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 22577062

Group type: EXPERIMENTAL
Intervention: Standardized protocol with a hydrogoniometer and 2 trained physical therapists
Number of subjects: 48
Study: 19387398

Group type: EXPERIMENTAL
Intervention: Thermogenic nutritional supplement
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 18644764

Group type: EXPERIMENTAL
Intervention: Health Promotion strategies (community participation and empowerment, contextualism, intersectorality, multistrategy, equity, and sustainability)
Number of subjects: 0
Study: 15860486

Group type: EXPERIMENTAL
Intervention: Intravenous darbepoetin alfa
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Subcutaneous darbepoetin alfa
Number of subjects: 118

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 118
Study: 11933033

Group type: EXPERIMENTAL
Intervention: Model-based approach for handling missing data
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard methods for dealing with missing data
Number of subjects: 0
Study: 9764983

Group type: EXPERIMENTAL
Intervention: HCV-related cryoglobulinemia
Number of subjects: 211

Group type: COMPARATOR
Intervention: Chronic hepatitis C
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: HCV genotype 1 and subtype 1b
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: HCV-RNA levels
Number of subjects: 211
Study: 7835116

Group type: EXPERIMENTAL
Intervention: Processed rhubarb (0.75g/day)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study: 10302610

Group type: EXPERIMENTAL
Intervention: Treatment booklet stressing the importance of recognizing information needs and encouraging patients to ask questions
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo education booklet similar in format but not in content
Number of subjects: 67
Study: 31724048

Group type: EXPERIMENTAL
Intervention: Cefiderocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best Available Therapy
Number of subjects: 0
Study: 28359784

Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 727

Group type: COMPARATOR
Intervention: Ipilimumab 3 mg/kg
Number of subjects: 727
Study: 26158622

Group type: EXPERIMENTAL
Intervention: 10 μg hepatitis B vaccine at 0, 1 and 3 months (group A)
Number of subjects: 5143

Group type: EXPERIMENTAL
Intervention: 10 μg hepatitis B vaccine at 0, 1 and 6 months (group B)
Number of subjects: 5143

Group type: EXPERIMENTAL
Intervention: 10 μg hepatitis B vaccine at 0, 1 and 12 months (group C)
Number of subjects: 5143

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 5143
Study: 22944555

Group type: EXPERIMENTAL
Intervention: Ketamine-low-dose midazolam (KM)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Midazolam-fentanyl (MF)
Number of subjects: 61
Study: 21496064

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg once daily with tamsulosin 0.4 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg once daily with tamsulosin 0.4 mg
Number of subjects: 2
Study: 19656023

Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planing (FMSRP)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Partial-mouth scaling and root planing (PMSRP)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both FMSRP and PMSRP
Number of subjects: 36
Study: 17596049

Group type: EXPERIMENTAL
Intervention: Modified posteromedial release (Group A)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Modified complete subtalar release (Group B)
Number of subjects: 86
Study: 15520363

Group type: EXPERIMENTAL
Intervention: Paroxetine (10-50 mg/d)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 322
Study: 11261519

Group type: EXPERIMENTAL
Intervention: Anticardiolipin antibodies (ACA) testing
Number of subjects: 296

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 296
Study: 9204356

Group type: EXPERIMENTAL
Intervention: Iopentol (Imagopaque 300 mg I/ml)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ioxaglate (Hexabrix 320 mg I/ml)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both iopentol and ioxaglate
Number of subjects: 120
Study: 7524945

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (Trasylol; Bayer AG, Leverkusen, Germany) administered intraperitoneally
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no aprotinin treatment)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 3454656

Group type: EXPERIMENTAL
Intervention: Quadriceps femoris muscle setting (QS) exercises
Number of subjects: 30

Group type: COMPARATOR
Intervention: Straight-leg-raising (SLR) exercises
Number of subjects: 30
Study: 2707520

Group type: EXPERIMENTAL
Intervention: Silymarin 420 mg/day
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 30703190

Group type: EXPERIMENTAL
Intervention: ADT plus docetaxel (70 mg/m2 every 3 weeks for 6 cycles)
Number of subjects: 254

Group type: COMPARATOR
Intervention: ADT alone
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: ADT plus docetaxel
Number of subjects: 254
Study: 28892526

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg/d for 5 days followed by 15 or 20 mg/d
Number of subjects: 195

Group type: COMPARATOR
Intervention: Warfarin with a target INR of 2.0-3.0 for 4 weeks
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 195

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 195
Study: 25482300

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hs-CRP) and Epstein-Barr virus DNA (EBV DNA) assessment
Number of subjects: 6337

Group type: EXPERIMENTAL
Intervention: High EBV DNA levels and high hs-CRP level
Number of subjects: 6337

Group type: EXPERIMENTAL
Intervention: High EBV DNA but low hs-CRP level or high hs-CRP but low EBV DNA
Number of subjects: 6337

Group type: EXPERIMENTAL
Intervention: Combined interpretation of EBV DNA with hs-CRP levels
Number of subjects: 6337
Study: 23299607

Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol, 2000 IU/d
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 20853132

Group type: EXPERIMENTAL
Intervention: Metronomic etoposide (50 mg/m2 daily for 21 consecutive days each month) with bevacizumab (10 mg/kg every 2 weeks)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Metronomic temozolomide (50 mg/m2 daily) with bevacizumab (10 mg/kg every 2 weeks)
Number of subjects: 23
Study: 20001979

Group type: EXPERIMENTAL
Intervention: Carvedilol (monotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol (in combination with nifedipine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol (in combination with nifedipine, metformin, and simvastatin)
Number of subjects: 0
Study: 17408310

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 70

Group type: COMPARATOR
Intervention: Other QTc interval-prolonging drugs
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Clinical studies
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Epidemiological studies
Number of subjects: 70
Study: 15012622

Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 11710890

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study: 9272421

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg daily)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg twice daily)
Number of subjects: 44
Study: 7949808

Group type: EXPERIMENTAL
Intervention: Continuous non-invasive finger artery pressure monitoring (Finapres) during active standing
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Active standing test with continuous beat-to-beat blood pressure recording
Number of subjects: 34
Study: 3069521

Group type: EXPERIMENTAL
Intervention: Nimesulide 200 mg/day for 7 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Flurbiprofen 300 mg/day for 7 days
Number of subjects: 60
Study: 28950757

Group type: EXPERIMENTAL
Intervention: Ringer's chase (RC) technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Infusion bag (IB) technique
Number of subjects: 40
Study: 27006119

Group type: EXPERIMENTAL
Intervention: Coronary CT Angiography (CCTA)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard evaluation
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 1000
Study: 24562444

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (RT)
Number of subjects: 1234

Group type: COMPARATOR
Intervention: Standard radiotherapy (RT)
Number of subjects: 1234
Study: 22794219

Group type: EXPERIMENTAL
Intervention: Vortex files (30/.04)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: EndoSequence files (30/.04)
Number of subjects: 16

Group type: COMPARATOR
Intervention: EndoSequence files (40/.04)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vortex files (40/.04)
Number of subjects: 16
Study: 21193871

Group type: EXPERIMENTAL
Intervention: Recombinant human TSH (0.9 mg injections on days 1 and 2)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (48 matched controls)
Number of subjects: 45
Study: 17114205

Group type: EXPERIMENTAL
Intervention: Intravenous disodium pamidronate (APD) given as monthly infusions
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intravenous disodium pamidronate (APD)
Number of subjects: 11
Study: 16269830

Group type: EXPERIMENTAL
Intervention: Safflower oil (n = 40)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Coconut oil (n = 40)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No oil control (n = 40)
Number of subjects: 120
Study: 14574343

Group type: EXPERIMENTAL
Intervention: Moderate physical activity (20 min brisk walking)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Snack (58.5 g chocolate-based)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (sitting, TV-watching)
Number of subjects: 10
Study: 10522579

Group type: EXPERIMENTAL
Intervention: 2 min saline-anesthetic interval
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 5 min saline-anesthetic interval
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 10 min saline-anesthetic interval
Number of subjects: 73
Study: 8747265

Group type: EXPERIMENTAL
Intervention: Electric stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bone graft substitutes (allograft, xenograft)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Osteoinductive growth factors
Number of subjects: 0
Study: 1718700

Group type: EXPERIMENTAL
Intervention: Nifedipine 30 to 120 mg/day, initiated as early as 3 hours after onset of symptoms, for up to 6 months
Number of subjects: 8670

Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg/day, started 7 to 21 days after infarction
Number of subjects: 8670

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 8670

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8670
Study: 7049112

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy using cyclophosphamide, methotrexate, and vincristine for 30 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 23
Study: 28634625

Group type: EXPERIMENTAL
Intervention: Personalized dietary intervention based on Mediterranean Diet (MD)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Updated American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention (Control)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Comparison of both groups at the end of the study
Number of subjects: 70
Study: 27027620

Group type: EXPERIMENTAL
Intervention: FineVision IOL
Number of subjects: 27

Group type: COMPARATOR
Intervention: Tecnis ZMB00 IOL
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both IOLs
Number of subjects: 27
Study: 24550581

Group type: EXPERIMENTAL
Intervention: Levosimendan pretreatment (Group L)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo pretreatment (Group C)
Number of subjects: 50
Study: 22232535

Group type: EXPERIMENTAL
Intervention: Transrectal ultrasound guided biopsy under antibiotic cover
Number of subjects: 1147
Study: 20576462

Group type: EXPERIMENTAL
Intervention: SCS intervention
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: sham-SCS intervention
Number of subjects: 28

Group type: COMPARATOR
Intervention: control intervention
Number of subjects: 28
Study: 18186676

Group type: EXPERIMENTAL
Intervention: One-stage tract dilation with a 30F Amplatz dilator
Number of subjects: 100
Study: 15891249

Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1% with doxycycline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxycycline alone
Number of subjects: 0
Study: 12146769

Group type: EXPERIMENTAL
Intervention: Active brace
Number of subjects: 30

Group type: COMPARATOR
Intervention: Plaster cast
Number of subjects: 30
Study: 9469998

Group type: EXPERIMENTAL
Intervention: Surfactant (beractant) 100 mg/kg, four doses before ECMO and four additional doses during ECMO if required
Number of subjects: 328

Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 328
Study: 7610735

Group type: EXPERIMENTAL
Intervention: Diltiazem (0.25-0.30 mg/kg BW)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Disopyramide (50 mg)
Number of subjects: 50
Study: 1978613

Group type: EXPERIMENTAL
Intervention: Vecuronium with TOF nerve stimulation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Vecuronium without TOF nerve stimulation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pancuronium with TOF nerve stimulation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Pancuronium without TOF nerve stimulation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Vecuronium and Pancuronium groups
Number of subjects: 80
Study: 332488

Group type: EXPERIMENTAL
Intervention: Toothpaste containing amyloglucosidase and glucose oxidase
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 29
Study: 31246976

Group type: EXPERIMENTAL
Intervention: HDL functionality
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: LDL atherogenicity
Number of subjects: 506

Group type: COMPARATOR
Intervention: Type-2 diabetes
Number of subjects: 506

Group type: COMPARATOR
Intervention: Dyslipidemia
Number of subjects: 506

Group type: COMPARATOR
Intervention: High body mass index
Number of subjects: 506

Group type: COMPARATOR
Intervention: Male sex
Number of subjects: 506

Group type: COMPARATOR
Intervention: Greater age
Number of subjects: 506
Study: 28108992

Group type: EXPERIMENTAL
Intervention: Intralesional injection of candida antigen, repeated every 3 weeks until complete improvement or for a maximum of three sessions.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cryotherapy with liquid nitrogen for a maximum of ten sessions or until clearance of all lesions.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intralesional injection of candida antigen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cryotherapy with liquid nitrogen
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intralesional immunotherapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 60
Study: 25864134

Group type: EXPERIMENTAL
Intervention: Marijuana use
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Craving for marijuana
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Academic self-efficacy
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Average minutes spent smoking marijuana
Number of subjects: 57
Study: 23921339

Group type: EXPERIMENTAL
Intervention: Double-bundle technique
Number of subjects: 103

Group type: COMPARATOR
Intervention: Single-bundle technique
Number of subjects: 103
Study: 20680245

Group type: EXPERIMENTAL
Intervention: Compaction by serial dilation (group SD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Extraction drilling (group ED)
Number of subjects: 40
Study: 19341921

Group type: EXPERIMENTAL
Intervention: Combined osteotomy (CO)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Closing-wedge osteotomy (CWO)
Number of subjects: 91
Study: 17308968

Group type: EXPERIMENTAL
Intervention: Levodopa treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15523954

Group type: EXPERIMENTAL
Intervention: Wavefront-guided ablation with Zyoptix technique (Group A: flap lift with epitheliorhexis)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Wavefront-guided ablation with Zyoptix technique (Group B: microkeratome recut)
Number of subjects: 13
Study: 11535769

Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 18
Study: 9629992

Group type: EXPERIMENTAL
Intervention: 40 mg furosemide
Number of subjects: 23
Study: 8768057

Group type: EXPERIMENTAL
Intervention: 0.06 mg ethinyl estradiol (EE2) for 14 days followed by 0.04 mg EE2 and 0.125 mg levonorgestrel for 12 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo treatment over 26 days
Number of subjects: 21
Study: 2148697

Group type: EXPERIMENTAL
Intervention: Low-dose heparin prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjusted-dose heparin treatment and various schedules of warfarin prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin fractions or fragments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study: 7028242

Group type: EXPERIMENTAL
Intervention: Standard therapy with intravenous Poly I:C
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard therapy without intravenous Poly I:C
Number of subjects: 32
Study: 31918942

Group type: EXPERIMENTAL
Intervention: FFR guidance
Number of subjects: 350

Group type: COMPARATOR
Intervention: OCT imaging guidance
Number of subjects: 350
Study: 31264114

Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 28671095

Group type: EXPERIMENTAL
Intervention: Combination of locking plate and anti-osteoporosis drug
Number of subjects: 120

Group type: COMPARATOR
Intervention: Simple locking plate treatment
Number of subjects: 120
Study: 25048788

Group type: EXPERIMENTAL
Intervention: Kaledo board game intervention introduced weekly for 20 weeks
Number of subjects: 3110

Group type: EXPERIMENTAL
Intervention: Kaledo board game intervention
Number of subjects: 3110
Study: 23897950

Group type: EXPERIMENTAL
Intervention: Telepsychiatry sessions (6 sessions) followed by caregiver behavior training session delivered in-person by a local therapist.
Number of subjects: 223

Group type: COMPARATOR
Intervention: Single telepsychiatry consultation (Control group).
Number of subjects: 223
Study: 21227890

Group type: EXPERIMENTAL
Intervention: VCS 0.4 mg kg(‐1) BID
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: VCS 0.3 mg kg(‐1) BID
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: VCS 0.2 mg kg(‐1) BID
Number of subjects: 451

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study: 19762041

Group type: EXPERIMENTAL
Intervention: Xenograft (porcine grafts of small intestinal submucosa or dermal collagen)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Polypropylene grafts (control group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Xenograft
Number of subjects: 50

Group type: COMPARATOR
Intervention: Polypropylene
Number of subjects: 50